| Where the guideline stands | Conditionally recommended against, on low certainty evidence |
| Availability | In clinic |
| How long before you judge it | n/a |
| Pregnancy | n/a |
| Sources behind this page | 5, every one linked at the bottom |
What it is
Pneumatic broadband light, also called photopneumatic therapy, combines gentle suction with a broad-spectrum light pulse in a single handpiece. The stated rationale has two parts: the vacuum lifts a small area of skin into the tip, stretching the follicle and helping to empty some of its contents, while also drawing the target tissue closer to the light source and pushing blood out of the way so that lower light energies can be used. The light itself spans a wide band of wavelengths rather than one narrow peak. It is given in clinic as a course of sessions, typically weekly, and is normally sold as an addition to a topical regimen rather than as a replacement for one.
What the evidence actually shows
Recommendation 5.1 reads: “For patients with acne, we conditionally recommend against adding pneumatic broadband light to adapalene 0.3% gel.” Its strength is conditional and its certainty is low. Those are separate axes. Low certainty describes how confident the work group is in the effect estimate; conditional against describes where the balance of benefits, harms, cost and burden falls given that uncertainty. It is the only recommendation against anything in the entire guideline; every other statement is for something, or says the evidence is insufficient to decide.
The evidence is essentially one study: a split-face, single-blind, randomised controlled trial published in Cutis in 2016 by Tangjaturonrusamee, Rattanaumpawan and Ditre. Eleven patients with mild to moderate acne, aged 18 to 35, applied adapalene 0.3% gel to the whole face nightly for ten weeks; one randomly assigned side also received pneumatic broadband light weekly for the first six weeks. Eight participants, 73%, completed.
What it found matters more than its headline. At week three the combination side showed a significantly greater reduction in non-inflammatory lesions (P=.04), and the modified global acne grading score improved significantly more on the combination side at weeks three and four (P=.05). By week four there was no significant difference in either inflammatory or non-inflammatory lesion counts. At the week ten follow-up, both sides had improved markedly, with no significant difference between them. The authors’ own conclusion was optimistic: that adding the device “may lead to quicker results and therefore may improve treatment adherence to topical therapies in acne patients.” The work group read the same data and saw a transient, unsustained head start bought with six weekly clinic visits, cost, and two withdrawals for hyperpigmentation.
That is why this lands as a recommendation against rather than as insufficient evidence: unlike the other devices, there was a direct randomised comparison of the add-on against the topical alone, and it showed no durable added benefit.
How it is actually used
There is nothing to plan here, because the guideline’s advice is not to add it. In the trial that produced the recommendation, adapalene 0.3% gel alone did the work: both sides of the face improved substantially by week ten. If you are already using adapalene 0.3% and are impatient with the pace, the honest reading of that trial is that the topical gets to the same place on its own, over the usual eight to twelve weeks. If a clinic offers pneumatic broadband light as an add-on to a retinoid, it is reasonable to ask what evidence they are relying on, and to mention that the AAD guideline conditionally recommends against exactly that combination. One precision point: this recommendation is about the device added to adapalene 0.3% gel. Pneumatic broadband light used alone, or with a different topical, was not graded either way.
Safety and who should avoid it
In the trial, the treatment itself was not especially painful; the median pain rating across all sessions was 1 on the Wong-Baker scale, described as “hurts a little bit”. Transient redness occurred in every participant, and the dryness from adapalene was described as tolerable. The meaningful harm was pigmentary: both Black participants in the study developed hyperpigmentation from the pneumatic broadband light and withdrew. With only eleven people enrolled, two withdrawals cannot be turned into a reliable rate, but it is a clear signal that the risk in darker skin was not adequately characterised by this trial, and no larger one has characterised it since. There are no long-term safety data and no pregnancy data.
Commonly repeated: “Insufficient evidence” and “recommended against” are the same verdict. What the evidence actually shows: They are meaningfully different. The 2024 guideline contains six separate insufficient-evidence statements, each meaning the work group could not decide either way. Recommendation 5.1 is the one place it did decide, and decided against, and that decision applies specifically to pneumatic broadband light added to adapalene 0.3% gel, not to light devices in general.
Sources
- Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris, J Am Acad Dermatol 2024
- Guideline Central. 2024 AAD Acne Vulgaris Clinical Guideline Summary (verbatim recommendation wording, strength and certainty ratings; recommendations are unnumbered on this page)
- Tangjaturonrusamee C, Rattanaumpawan P, Ditre CM. Comparison of pneumatic broadband light plus adapalene gel 0.3% versus adapalene gel 0.3% monotherapy in the treatment of mild to moderate acne, Cutis 2016;98(1):56-61
- Full text of the Cutis 2016 pneumatic broadband light trial (MDedge reprint)
- Aetna Clinical Policy Bulletin 0656: Phototherapy for Acne (lists photopneumatic therapy as experimental/investigational)
Keep reading
See where this sits against every other acne treatment on the acne treatment evidence map, or check how it combines with another ingredient in the ingredient combination checker. For the guideline’s own wording on this, see the 2024 AAD guideline, recommendation by recommendation.
Not medical advice
This page reports what the published evidence says about a treatment. It is not a treatment plan and it cannot account for your skin, your other medications or your medical history. Nothing here has been reviewed by a clinician; see our editorial policy for what that means. Talk to a clinician before starting or stopping any prescription treatment.
